SAN DIEGO, May 4, 2016 /PRNewswire/ -- Exosome Sciences,
Inc., in collaboration with majority shareholder Aethlon Medical, Inc., (Nasdaq: AEMD) announced today that it will initiate
production of its ELLSA™ (Enzyme Linked Lectin Specific Assay) diagnostic platform to isolate disease-specific exosomes from
bodily fluids. Exosome Sciences, Inc. (ESI) will make the platform available to collaborative institutes that are
conducting research on exosomal biomarkers with the eventual goal of supporting a new generation of diagnostic
products.
Similar to an enzyme-linked immunosorbent assay (the basis of most modern medical diagnostic testing), the ELLSA is coated
with an affinity capture lectin; the same lectin that is used in the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class
broad-spectrum treatment countermeasure against life-threatening viral infections and also is being studied for its potential to
address tumor-secreted exosomes that circulate in the bloodstream to spread metastasis and suppress the immune system of cancer
patients.
Beyond its potential use as a companion diagnostic to support Hemopurifier therapy, ESI believes the ELLSA platform may appeal
to collaborators who seek to isolate disease-specific exosomes as the basis for new diagnostic candidates. Prior to the
formal launch of its ESI diagnostic subsidiary, Aethlon produced the ELLSA platform on a limited basis to support beta-testing
research programs. Exosomal biomarkers have since emerged to become candidates to detect a broad-spectrum of diseases,
including cancer, viral infections and neurological conditions. Exosomes transport disease origin RNA, DNA and proteins
that can be isolated from the urine, blood components, saliva and most other bodily fluids.
Preliminary HIV Exosome Data
ESI also disclosed that an investigational study conducted by researchers at the Morehouse School of
Medicine, demonstrated for the first time that urinary exosomes isolated from HIV-infected individuals contain HIV
specific proteins that may serve as a potential diagnostic tool. In the study, the researchers utilized the ELLSA platform
to isolate urinary exosomes followed by an antibody step to detect HIV-specific exosomes. The Morehouse team reported that
the diagnostic protocol accurately identified HIV-specific exosomes in 111 HIV-infected individuals, but not in the urine of 35
HIV negative control subjects. The detection of HIV-specific exosomes in the urine could represent a simple noninvasive
global strategy to diagnose HIV infection. Follow-on clinical studies are currently be evaluated.
Preliminary Chronic Traumatic Encephalopathy (CTE) TauSome Data
ESI recently disclosed the published preliminary results of the first candidate blood test to detect the neurodegenerative
disease Chronic Traumatic Encephalopathy (CTE) in living individuals. CTE is associated with exposure to repetitive head
impacts, such as those experienced by American football players, and at presents is only be diagnosed through post-mortem
autopsy. The study outcomes were based on ESI's discovery of an exosome-based biomarker known as a
TauSome(™).
In the study, researchers examined 78 former National Football League (NFL) players and a control group of 16 former
non-contact sport athletes. All subjects were participants in a larger project that was funded by a grant from the National
Institutes of Health to develop a variety of biomarkers for CTE conducted at Boston University School of
Medicine. The study demonstrated that TauSome levels were approximately 9x higher on average in the NFL group as compared
to the control group. Additionally, TauSome levels in the NFL group were significantly correlated with performance on
standardized tests of memory and psychomotor speed. Meaning, the higher the TauSome level, the worse the study participant
performed. A series of future TauSome studies have been planned, including the potential use of the ELLSA platform for
TauSome isolation, as well as follow-on TauSome testing as part of a $16 million grant awarded to
the Boston University team by the NIH to develop methods of diagnosing CTE during life.
About Aethlon Medical, Inc.
Aethlon Medical (Nasdaq:AEMD) creates affinity biofiltration devices to treat life-threatening diseases. The Aethlon
Hemopurifier® is a leading broad-spectrum treatment countermeasure against infectious viral pathogens. The device, which
has been successfully administered to individuals infected with HIV, Hepatitis C (HCV) and Ebola virus, is currently the subject
of FDA approved clinical studies. Aethlon is also studying the potential use of the Hemopurifier® to address exosomes secreted by
tumors to promote the spread of metastasis and suppress the immune system of cancer patients. The Company provides
government contracting services to the Defense Advanced Research Projects Agency (DARPA) related to the development of a
biofiltration device to treat sepsis and maintains majority ownership of Exosome Sciences, Inc., which is focused on the
discovery of exosomal biomarkers to diagnose and monitor Chronic Traumatic Encephalopathy (CTE) and other neurological
disorders. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as
"may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions
constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and
actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute
to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or
any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that
the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the
Company's products, including products developed by Exosome Sciences, Inc., the Company's ability to raise capital when needed,
the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products
either internally or through outside companies, the impact of government regulations, patent protection on the Company's
proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product
liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing
list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ
materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended March 31, 2015, and in the Company's other filings
with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake
any duty, to update this information to reflect future events or circumstances.
Contacts:
Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc
212-986-6667
smarg@braincomm.com
Logo - http://photos.prnewswire.com/prnh/20130912/LA78266LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medicals-exosome-sciences-announces-production-of-ellsa-exosome-isolation-platform-300262503.html
SOURCE Aethlon Medical, Inc.